Interactions between Hsp90, Co-chaperones and Client Proteins
Hsp90、共伴侣和客户蛋白之间的相互作用
基本信息
- 批准号:8824184
- 负责人:
- 金额:$ 37.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-01 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse reactionsAffinityBackBindingBinding SitesC-terminalCell ExtractsCell physiologyCellsClientComplexConsensusConsensus SequenceCrowdingCytoplasmDNA Binding DomainDataDiseaseElectron MicroscopyEnvironmentEukaryotaEukaryotic CellFluorescenceGlucocorticoid ReceptorGoalsHis-His-His-His-His-HisHistidineHomeostasisHumanIn VitroIncentivesIntegration Host FactorsLengthLigand Binding DomainLigandsLiteratureLocationMammalian CellMeasurableMeasurementMediatingMembraneMethodsMolecular ChaperonesMolecular ConformationMovementMutateNMR SpectroscopyNatureOrganellesPathway interactionsPeptidesPhosphotransferasesPlayPreparationProcessProtein BindingProteinsReportingResearchRoentgen RaysRoleSamplingSeriesSiteSolutionsStretchingStructureSystemTailTemperatureThinkingWorkYeastsZincbasechaperonindimerinnovationinsightnoveloperationphysical statepreventprotein complexprotein foldingprotein functionprotein p23protein protein interactionpublic health relevanceresearch studysteroid hormone receptortooltranscription factor
项目摘要
DESCRIPTION (provided by applicant): In eukaryotes, the chaperone Hsp90 and its co-chaperones interact with and stabilize a number of crucially important cellular factors, including steroid hormone receptors, cellular kinases and transcription factors. Although a great deal is known about chaperone and co-chaperone structure, the structural basis for the interaction between Hsp90 and its clients remains unknown. The fundamental problem is that we still do not understand the physical state of the client protein when it is bound to the Hsp90 chaperone, and we have only a rough idea of where on the Hsp90 molecule the client protein makes contact. Part of the difficulty with obtaining data on these systems is that the client proteins ar generally extremely difficult to prepare in quantities suitable for structural analysis. Doubtless this is a major incentive for the cell to employ Hsp90 in their stabilization. We propose innovative methods of preparation of client protein-Hsp90 complexes, by addition of other necessary components of the chaperone cascade of the eukaryotic cell and by re-thinking the likely form of a high-affinity client protein. Our first aim will be to characterize interactions between a zinc-free form of the transcription factor p53 and the full-length Hsp90 dimer, using a set of structural measurements that can interrogate such a large complex. These measurements include small-angle X-ray scattering, room- temperature EPR, fluorescence methods and electron microscopy. The second specific aim will be concerned with the effect of co-chaperones on the system. Preliminary data show that there is a measurable interaction between the p53 DBD client protein and the p23 co-chaperone. NMR spectroscopy and other methods will be used to characterize this binary interaction, as well as the ternary interaction that we observe with the addition of Hsp90. In the third specific aim, we will examine the complex of the glucocorticoid receptor ligand-binding domain (GR-LBD) and Hsp90, adapting methods that have been used in the literature to demonstrate the presence of this interaction in mammalian cell extracts. A new preparation method for the complex includes the over-expression of a histidine-tagged GR-LBD protein together with the incorporation of accessory proteins from the chaperone cascade in the preparation of the complex. The successful conclusion of the proposed work will give important new insights not only into the specific nature of the chaperone-client protein complex, but also into the range of structural states sampled by proteins in their cellular environments: we have only recently begun to appreciate that protein conformational states other than the "fully and stably folded" states typified by traditional structural studies may be present and fully functional in the cell.
描述(由申请人提供):在真核生物中,分子伴侣Hsp 90及其辅助分子伴侣与许多至关重要的细胞因子相互作用并使其稳定,所述细胞因子包括类固醇激素受体、细胞激酶和转录因子。虽然我们对分子伴侣和共分子伴侣的结构已经有了很大的了解,但Hsp 90与其客户之间相互作用的结构基础仍然是未知的。根本的问题是,我们仍然不了解客户蛋白质与Hsp 90分子伴侣结合时的物理状态,我们对客户蛋白质在Hsp 90分子上的接触位置只有一个粗略的想法。在这些系统上获得数据的部分困难在于客户蛋白质通常极难以适合于结构分析的量制备。毫无疑问,这是细胞在其稳定过程中使用Hsp 90的主要动机。我们提出了创新的客户端蛋白-热休克蛋白90复合物的制备方法,通过添加其他必要的成分的伴侣级联的真核细胞和重新思考的可能形式的高亲和力的客户端蛋白。我们的第一个目标将是表征无锌形式的转录因子p53和全长热休克蛋白90二聚体之间的相互作用,使用一组结构测量,可以询问这样一个大的复杂。这些测量包括小角X射线散射、室温EPR、荧光方法和电子显微镜。第二个具体目标将涉及共同监护人对系统的影响。初步数据显示,在p53 DBD客户蛋白和p23共伴侣蛋白之间存在可测量的相互作用。NMR光谱和其他方法将被用来表征这种二元相互作用,以及我们观察到的三元相互作用与热休克蛋白90的添加。在第三个具体的目标,我们将研究糖皮质激素受体配体结合域(GR-LBD)和热休克蛋白90的复合物,适应的方法,已在文献中使用,以证明这种相互作用的存在下,在哺乳动物细胞提取物。该复合物的新制备方法包括组氨酸标记的GR-LBD蛋白的过表达以及在复合物的制备中掺入来自伴侣级联的辅助蛋白。拟议工作的成功结束不仅将为伴侣-客户蛋白复合物的特定性质提供重要的新见解,而且还将为蛋白质在其细胞环境中采样的结构状态范围提供重要的新见解:我们只是最近才开始认识到,除了“完全和稳定折叠”的蛋白质构象状态,由传统结构研究代表的状态可以在细胞中存在并完全起作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HELEN JANE DYSON其他文献
HELEN JANE DYSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HELEN JANE DYSON', 18)}}的其他基金
Interactions between Hsp90, Co-chaperones and Client Proteins
Hsp90、共伴侣和客户蛋白之间的相互作用
- 批准号:
9269592 - 财政年份:2015
- 资助金额:
$ 37.9万 - 项目类别:
相似海外基金
A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
- 批准号:
MR/X00094X/1 - 财政年份:2022
- 资助金额:
$ 37.9万 - 项目类别:
Research Grant
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
- 批准号:
22K06738 - 财政年份:2022
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
- 批准号:
22K15910 - 财政年份:2022
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 37.9万 - 项目类别:
Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
- 批准号:
19K17779 - 财政年份:2019
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
- 批准号:
18K00267 - 财政年份:2018
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
- 批准号:
379425 - 财政年份:2018
- 资助金额:
$ 37.9万 - 项目类别:
Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
- 批准号:
9576448 - 财政年份:2017
- 资助金额:
$ 37.9万 - 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
- 批准号:
16K15156 - 财政年份:2016
- 资助金额:
$ 37.9万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
- 批准号:
367156 - 财政年份:2016
- 资助金额:
$ 37.9万 - 项目类别:
Studentship Programs